Trial Profile
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Ponatinib (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Methotrexate
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 26 Feb 2024 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.
- 26 Feb 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Nov 2025.
- 12 Dec 2023 Results(Between June 2018 and May 2023, n=62 pts) presented at the 65th American Society of Hematology Annual Meeting and Exposition